- Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
- Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
- Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
- Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
- Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
- Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
- Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
- Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
- Can-Fite Reports 2022 Financial Results & Provides Clinical Update
- Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
Can Fite Biopharma Ltd (CF5:DEU) closed at 0.61, 0.00% above its 52-week low of 0.61, set on Jan 17, 2023.
0.61Jan 17 202311.20Jun 29 2022
Data delayed at least 15 minutes, as of Jan 17 2023 07:26 GMT.